Neumora Therapeutics, Inc. (NMRA)
0.4999
-0.05
(-9.11%)
USD |
NASDAQ |
Oct 02, 16:00
0.4984
0.00 (0.00%)
After-Hours: 20:00
Neumora Therapeutics Net Income (Quarterly) : -43.08M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -43.08M |
| March 31, 2026 | -53.46M |
| December 31, 2025 | -59.45M |
| September 30, 2025 | -56.76M |
| June 30, 2025 | -52.73M |
| March 31, 2025 | -67.99M |
| December 31, 2024 | -58.82M |
| September 30, 2024 | -72.55M |
| June 30, 2024 | -58.70M |
| March 31, 2024 | -53.72M |
| Date | Value |
|---|---|
| December 31, 2023 | -108.73M |
| September 30, 2023 | -53.03M |
| June 30, 2023 | -38.54M |
| March 31, 2023 | -35.62M |
| December 31, 2022 | -28.15M |
| September 30, 2022 | -29.34M |
| June 30, 2022 | -30.37M |
| March 31, 2022 | -43.04M |
| March 31, 2021 | -15.30M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| BioAge Labs, Inc. | -26.10M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 43.08M |
| EPS Diluted (Quarterly) | -0.2327 |
| Enterprise Value | 29.82M |
| Earnings Yield | -246.7% |
| Normalized Earnings Yield | -242.39 |